Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 8Myeloid 7Tumor-Agnostic 3Gynecologic 2Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 26Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 20Paclitaxel 12Carboplatin 10Blood Specimen Collection 10Bevacizumab 10atezolizumab 9Standard of Care 9Nivolumab 9Cisplatin 8Radiosurgery 7Pemetrexed 7Gemcitabine 6Cyclophosphamide 6Capecitabine 6trastuzumab deruxtecan 5durvalumab 5X-Rays 5Taxes 5Surveys and Questionnaires 5Irinotecan 5Fluorouracil 5olaparib 4niraparib 4cabozantinib 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
nilotinib × Tumor-Agnostic × 90 days × Clear all
NCT02379416 2026-06-01

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
47 enrolled
Tumor-Agnostic

Neoplasms

NCT04449549 2026-05-22

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
82 enrolled
Tumor-Agnostic

Neoplasms

NCT05554341 2026-05-14

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡